Objective: Male breast cancer (MBC) is rarely seen in male sex with a prevalence in the general population of approximately 1 per 100,000. Our aim was to determine retrospectively the clinicopathological features and overall survival at 22 male invasive breast carcinoma cases with the molecular sub-types based on immunohistochemistry in nine years period.
Methods: All male patients presenting with invasive breast carcinoma between January 2006 and September 2014 data were recorded regarding age, clinical presentation, operative procedure, tumor size, histologic type, grade, lymph node involvement, immunohistochemical results of HER-2, hormone receptors, Ki-67 and p53 with stage and outcome.
Results: The mean age of the group was 68.05 years with a 72.7% had performed a modified radical mastectomy (MRM). The mean diameter of tumors was 2.63 cm and the most common histologic type was invasive ductal carcinoma (IDC). Notably there was no grade I tumor and Luminal B type had slightly high in number.
Conclusion: We found a significant correlation in between luminal molecular subtype and Ki67 proliferation. The mean overall survival time was 75.3 months. Luminal subtypes were not showed significant difference with overall survival time.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.